此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

中国肺球囊成形术的安全性和有效性

Balloon pulmonary angioplasty (BPA) is a potential treatment for patients with pulmonary artery stenosis, including non-operable patients with chronic thromboembolic pulmonary hypertension (CTEPH), takayasu arteritis and fibrosis mediastinitis.

The aim of this study was to evaluate the safety and efficacy of BPA in CTEPH and patients not amenable to pulmonary endarterectomy(PEA) or suffered from persistent CTEPH after PEA, , takayasu arteritis and fibrosis mediastinitis.

研究概览

详细说明

This study is a prospective, multi-center, long-term observational project to study the safety and efficacy of BPA. Clinical evaluation, including: functional capacity, 6-minutes walking test, biomarkers, cardiopulmonary exercise test, electrocardiography, echocardiography, haemodynamics, pulmonary angiography and lung scintigraphy was performed before the initiation therapy of BPA, and 3-12 months after last session of BPA.

we also aim to evaluate the value of FAPI in predicting the efficacy and the prognosis of patients with CTEPH who received BPA.

研究类型

观察性的

注册 (估计的)

2000

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Beijing、中国、100037
        • 招聘中
        • center of pulmonary vascular disease, Fuwai hospital
        • 接触:
        • 首席研究员:
          • Zhihong Liu, MD,PhD
      • Beijing、中国、100037
        • 招聘中
        • Chinese Academy of Medical Sciences Fuwai hospital
        • 接触:
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Chronic thromboembolic pulmonary hypertension patients admitted in hospital.

描述

Inclusion Criteria:

  1. diagnosed with CTEPH according to ESC Guidelines (1) Mean PAP ≥ 25mmHg at rest; or if mean PAP < 25mmHg at rest, have exercise limitations from chronic thromboembolic disease (2)Abnormal ventilation perfusion lung scanning (VQ) scan, pulmonary angiogram, computer tomographic pulmonary angiogram, or magnetic resonance pulmonary angiogram confirming chronic thromboembolic disease as recommended by standard guidelines
  2. Treatment with anticoagulation for ≥ 3 months before diagnosis of CTEPH
  3. Not amenable to pulmonary endarterectomy
  4. Willing to provide informed consent

Exclusion Criteria:

  1. Patients unwilling or unable to provide written consent for participation in the study.
  2. Impossible to follow up.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of Treatment-Emergent Adverse Events of BPA procedure.
大体时间:From initiation of BPA to 3-12 months after last session

Surveillance of complications including: vessel injury, desaturation, cough, mild hemoptysis (<50ml), severe hemoptysis (>50ml), reperfusion pulmonary injury, death.

From initiation of BPA to 3-12 months after last session
Change of Pulmonary artery pressure in mmHg caused by series of BPA.
大体时间:From initiation of BPA to 3-12 months after last session

Pulmonary artery pressure in mmHg is obtained by right cardiac catheterization.

From initiation of BPA to 3-12 months after last session
Change of Pulmonary vascular resistance (PVR) in Wood U caused by series of BPA.
大体时间:From initiation of BPA to 3-12 months after last session

Pulmonary vascular resistance (PVR) in Wood U is obtained by right cardiac catheterization.

From initiation of BPA to 3-12 months after last session
Change of cardiac index (CI) in L/m^2 caused by series of BPA.
大体时间:From initiation of BPA to 3-12 months after last session

Cardiac index (CI) in L/m^2 is obtained by right cardiac catheterization.

From initiation of BPA to 3-12 months after last session
Change of World Health Organization (WHO) functional capacity classification caused by series of BPA.
大体时间:From initiation of BPA to 3-12 months after last session

World Health Organization is obtained from electronic medical records.

From initiation of BPA to 3-12 months after last session
Change of six minutes walk distance in meter caused by series of BPA.
大体时间:From initiation of BPA to 3-12 months after last session

World Health Organization is obtained from electronic medical records.

From initiation of BPA to 3-12 months after last session
Change of N-terminal B-type natriuretic peptide in pg/ml caused by series of BPA.
大体时间:From initiation of BPA to 3-12 months after last session

World Health Organization is obtained from electronic medical records.

From initiation of BPA to 3-12 months after last session
Change of Peak VO2/kg in ml/min/kg caused by series of BPA.
大体时间:From initiation of BPA to 3-12 months after last session

Peak VO2/kg in ml/min/kg is obtained by cardiopulmonary exercise test.

From initiation of BPA to 3-12 months after last session
Change of diffusing capacity for carbon monoxide caused by series of BPA.
大体时间:From initiation of BPA to 3-12 months after last session

diffusing capacity for carbon monoxide in % is obtained from pulmonary function test

From initiation of BPA to 3-12 months after last session
Change of fibroblast activation protein inhibitor expression after BPA
大体时间:From initiation of BPA to 3-12 months after last session

Change of fibroblast activation protein inhibitor expression after BPA

From initiation of BPA to 3-12 months after last session

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2018年5月11日

初级完成 (估计的)

2065年5月11日

研究完成 (估计的)

2065年5月11日

研究注册日期

首次提交

2019年10月26日

首先提交符合 QC 标准的

2019年12月18日

首次发布 (实际的)

2019年12月20日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅